mr001
Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.monoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Triple-Negative Breast Cancer (TNBC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ivonescimab Cedars-Sinai Medical Center | Phase 3 | B |
esg401 Qilu Pharmaceutical Co., Ltd. | Phase 3 | B |
Iparomilimab Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2/3 | CCC |
Tuvonralimab Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2/3 | CCC |
js207 Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
mr001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →